#1 Clinical Trials Search in Europe

Chlorhexidine Digluconate Solution

This article discusses the use of Chlorhexidine Digluconate Solution in clinical trials, specifically focusing on its potential role in managing skin-related side effects in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). The trial aims to evaluate whether enhanced dermatologic management, which may include the use of Chlorhexidine Digluconate Solution, can reduce the incidence of certain skin-related adverse events in patients undergoing treatment with amivantamab and lazertinib.

Table of Contents

What is Chlorhexidine Digluconate Solution?

Chlorhexidine Digluconate Solution is a type of antiseptic medication used primarily for skin disinfection[1]. It belongs to a class of drugs known as antimicrobial agents, which are substances that kill or slow the growth of microorganisms like bacteria and fungi.

Uses of Chlorhexidine Digluconate Solution

Chlorhexidine Digluconate Solution is commonly used for:

  • Skin disinfection before medical procedures
  • Cleaning wounds
  • Preventing infections in minor cuts and burns
  • As part of oral hygiene routines (in lower concentrations)
  • Managing certain skin conditions

In the context of cancer treatment, it’s being studied for its potential role in managing skin-related side effects of certain cancer therapies[1].

How to Use Chlorhexidine Digluconate Solution

Chlorhexidine Digluconate Solution is typically applied directly to the skin. It’s important to follow these general steps:

  1. Clean the area to be treated
  2. Apply the solution gently using a clean cotton swab or as directed by your healthcare provider
  3. Allow the solution to dry completely
  4. Do not rinse off unless instructed to do so

Always follow your healthcare provider’s specific instructions, as they may vary depending on your individual situation.

Dosage Information

The dosage of Chlorhexidine Digluconate Solution can vary depending on its specific use and concentration. In the clinical trial information provided, the maximum daily dose was listed as 10 ml, with a maximum treatment period of 12 weeks[1]. However, it’s crucial to note that:

  • Your healthcare provider will determine the appropriate dosage for your specific needs
  • Never exceed the recommended dosage without consulting your doctor
  • The concentration of the solution can vary, so always check the product label carefully

Precautions and Side Effects

While Chlorhexidine Digluconate Solution is generally safe when used as directed, there are some precautions to keep in mind:

  • Do not use on deep wounds, animal bites, or serious burns without medical supervision
  • Avoid contact with eyes, ears, and mouth
  • If you experience any allergic reactions (such as rash, itching, or difficulty breathing), stop use immediately and seek medical attention
  • Inform your healthcare provider if you are pregnant, breastfeeding, or have any other medical conditions

Possible side effects may include skin irritation, dryness, or rarely, allergic reactions. Always report any unusual symptoms to your healthcare provider.

Current Research

Chlorhexidine Digluconate Solution is currently being studied in the context of cancer treatment. Specifically, it’s part of a clinical trial investigating enhanced dermatologic management for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) who are receiving targeted therapies[1].

The trial aims to evaluate whether enhanced skin care, which may include the use of Chlorhexidine Digluconate Solution, can reduce the incidence of severe skin-related side effects in these patients. This research could potentially lead to improved quality of life for cancer patients undergoing certain treatments.

It’s important to note that while this research is promising, Chlorhexidine Digluconate Solution should only be used as directed by a healthcare professional, especially in the context of cancer treatment.

Aspect Details
Study Type Phase 2, open-label, randomized trial
Primary Objective Evaluate if enhanced dermatologic management reduces Grade ≥2 DAEIs compared to standard care
Target Population Adults with locally advanced or metastatic EGFR-mutated NSCLC
Main Treatments Amivantamab and lazertinib
Dermatologic Management Enhanced vs. standard-of-care skin management
Chlorhexidine Digluconate Solution Role Part of enhanced dermatologic management strategy
Primary Endpoint Incidence of Grade ≥2 DAEIs in first 12 weeks of treatment
Key Exclusion Criteria Prior systemic treatment for advanced disease, active leptomeningeal disease, certain cardiovascular conditions

FAQ

  • What is the purpose of using Chlorhexidine Digluconate Solution in this clinical trial? Chlorhexidine Digluconate Solution is being studied as part of an enhanced dermatologic management strategy to potentially reduce skin-related side effects in patients receiving treatment for advanced lung cancer.
  • Who is eligible to participate in this clinical trial? Eligible participants are adults (18 years or older) with confirmed locally advanced or metastatic non-small cell lung cancer (NSCLC) that has specific EGFR mutations and has not been previously treated for advanced disease.
  • What treatments are being studied alongside Chlorhexidine Digluconate Solution? The main cancer treatments being studied are amivantamab and lazertinib. Chlorhexidine Digluconate Solution is part of the enhanced dermatologic management strategy being evaluated.
  • How long does the trial last? The primary endpoint of the trial focuses on the first 12 weeks after starting treatment with amivantamab and lazertinib. However, the total duration of the trial may be longer.
  • Are there any specific skin conditions that would exclude someone from participating? Yes, individuals with pre-existing skin conditions that would prevent adequate evaluation of dermatologic toxicity, as determined by the investigator, are excluded from the trial.

Ongoing Clinical Trials on Chlorhexidine Digluconate Solution

  • Study on Skin Care for Patients with Advanced EGFR-Mutated Lung Cancer Treated with Amivantamab and Lazertinib

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Spain

Glossary

  • EGFR: Epidermal Growth Factor Receptor, a protein on cells that helps them grow. Some NSCLC tumors have mutations in the EGFR gene.
  • NSCLC: Non-Small Cell Lung Cancer, a type of lung cancer that is the most common form of the disease.
  • Dermatologic Adverse Events of Interest (DAEIs): Specific skin-related side effects that are being monitored and evaluated in this clinical trial.
  • Amivantamab: A targeted therapy drug used in the treatment of certain types of NSCLC.
  • Lazertinib: Another targeted therapy drug used in combination with amivantamab for treating EGFR-mutated NSCLC.
  • Chlorhexidine Digluconate Solution: An antiseptic solution being studied as part of enhanced skin care management in this trial.
  • ECOG Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • Metastatic: Cancer that has spread from its original location to other parts of the body.
  • Phase 2 Trial: A stage of clinical research that tests a drug's effectiveness and further evaluates its safety in a larger group of people.

References

  1. http://clinicaltrials.eu/trial/study-on-skin-care-for-patients-with-advanced-egfr-mutated-lung-cancer-treated-with-amivantamab-and-lazertinib/